Importance: The appropriate treatment target for systolic blood pressure (SBP) in older patients with hypertension remains uncertain.
Objective: To evaluate the effects of intensive (<120 mm Hg) compared with standard (<140 mm Hg) SBP targets in persons aged 75 years or older with hypertension but without diabetes.
Design, setting, and participants: A multicenter, randomized clinical trial of patients aged 75 years or older who participated in the Systolic Blood Pressure Intervention Trial (SPRINT). Recruitment began on October 20, 2010, and follow-up ended on August 20, 2015.
Interventions: Participants were randomized to an SBP target of less than 120 mm Hg (intensive treatment group, n = 1317) or an SBP target of less than 140 mm Hg (standard treatment group, n = 1319).
Main outcomes and measures: The primary cardiovascular disease outcome was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in a myocardial infarction, nonfatal stroke, nonfatal acute decompensated heart failure, and death from cardiovascular causes. All-cause mortality was a secondary outcome.
Results: Among 2636 participants (mean age, 79.9 years; 37.9% women), 2510 (95.2%) provided complete follow-up data. At a median follow-up of 3.14 years, there was a significantly lower rate of the primary composite outcome (102 events in the intensive treatment group vs 148 events in the standard treatment group; hazard ratio [HR], 0.66 [95% CI, 0.51-0.85]) and all-cause mortality (73 deaths vs 107 deaths, respectively; HR, 0.67 [95% CI, 0.49-0.91]). The overall rate of serious adverse events was not different between treatment groups (48.4% in the intensive treatment group vs 48.3% in the standard treatment group; HR, 0.99 [95% CI, 0.89-1.11]). Absolute rates of hypotension were 2.4% in the intensive treatment group vs 1.4% in the standard treatment group (HR, 1.71 [95% CI, 0.97-3.09]), 3.0% vs 2.4%, respectively, for syncope (HR, 1.23 [95% CI, 0.76-2.00]), 4.0% vs 2.7% for electrolyte abnormalities (HR, 1.51 [95% CI, 0.99-2.33]), 5.5% vs 4.0% for acute kidney injury (HR, 1.41 [95% CI, 0.98-2.04]), and 4.9% vs 5.5% for injurious falls (HR, 0.91 [95% CI, 0.65-1.29]).
Conclusions and relevance: Among ambulatory adults aged 75 years or older, treating to an SBP target of less than 120 mm Hg compared with an SBP target of less than 140 mm Hg resulted in significantly lower rates of fatal and nonfatal major cardiovascular events and death from any cause.
Trial registration: clinicaltrials.gov Identifier: NCT01206062.
Conflict of interest statement
[The SPRINT Research. A Randomized Trial of Intensive versus Standard Blood-Pressure Control].Vnitr Lek. 2016 Jan;62(1):44-7. Vnitr Lek. 2016. PMID: 26967236 Clinical Trial. Czech.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. N Engl J Med. 2015. PMID: 26551272 Free PMC article. Clinical Trial.
Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey).Circulation. 2017 Apr 25;135(17):1617-1628. doi: 10.1161/CIRCULATIONAHA.116.025322. Epub 2017 Feb 13. Circulation. 2017. PMID: 28193605 Free PMC article.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.Lancet. 2016 Jan 30;387(10017):435-43. doi: 10.1016/S0140-6736(15)00805-3. Epub 2015 Nov 7. Lancet. 2016. PMID: 26559744 Review.
Blood pressure targets for hypertension in people with diabetes mellitus.Cochrane Database Syst Rev. 2013 Oct 30;(10):CD008277. doi: 10.1002/14651858.CD008277.pub2. Cochrane Database Syst Rev. 2013. PMID: 24170669 Review.
Cited by 191 articles
Resistance training affects the hemodynamic parameters of hypertensive and normotensive women differently, and regardless of performance improvement.J Exerc Sci Fit. 2020 Sep;18(3):122-128. doi: 10.1016/j.jesf.2020.03.003. Epub 2020 Mar 13. J Exerc Sci Fit. 2020. PMID: 32351589 Free PMC article.
Hypertension and Drug Adherence in the Elderly.Front Cardiovasc Med. 2020 Apr 7;7:49. doi: 10.3389/fcvm.2020.00049. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32318584 Free PMC article. Review.
Comparing Outcomes Between Thiazide Diuretics and Other First-line Antihypertensive Drugs in Long-term Nursing Home Residents.Clin Ther. 2020 Apr;42(4):583-591. doi: 10.1016/j.clinthera.2020.02.016. Epub 2020 Mar 27. Clin Ther. 2020. PMID: 32229030
Comparison and Implication of the Contemporary Blood Pressure Guidelines on Korean Population.Korean Circ J. 2020 Jun;50(6):485-498. doi: 10.4070/kcj.2019.0347. Epub 2020 Feb 18. Korean Circ J. 2020. PMID: 32212423 Free PMC article.
Association of pharmacological treatments for hypertension, diabetes, and dyslipidemia with health checkup participation and identification of disease control factors among older adults in Tokyo, Japan.Prev Med Rep. 2019 Dec 23;17:101033. doi: 10.1016/j.pmedr.2019.101033. eCollection 2020 Mar. Prev Med Rep. 2019. PMID: 32140383 Free PMC article.
- UL1 TR000433/TR/NCATS NIH HHS/United States
- UL1 TR001070/TR/NCATS NIH HHS/United States
- UL1TR000050/TR/NCATS NIH HHS/United States
- HHSN268200900046C/PHS HHS/United States
- 9U54TR000017-06/TR/NCATS NIH HHS/United States
- UL1 TR000445/TR/NCATS NIH HHS/United States
- HHSN268200900048C/HL/NHLBI NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- HHSN268200900040C/HL/NHLBI NIH HHS/United States
- UL1TR000093/TR/NCATS NIH HHS/United States
- HHSN268200900046C/HL/NHLBI NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UL1TR000073/TR/NCATS NIH HHS/United States
- UL1RR025755/RR/NCRR NIH HHS/United States
- UL1 TR000075/TR/NCATS NIH HHS/United States
- UL1RR025771/RR/NCRR NIH HHS/United States
- P30 GM103337/GM/NIGMS NIH HHS/United States
- UL1 TR001064/TR/NCATS NIH HHS/United States
- UL1TR000433/TR/NCATS NIH HHS/United States
- HHSN268200900040C/PHS HHS/United States
- UL1 RR025752/RR/NCRR NIH HHS/United States
- UL1TR000105-05/TR/NCATS NIH HHS/United States
- UL1 RR025771/RR/NCRR NIH HHS/United States
- UL1RR025752/RR/NCRR NIH HHS/United States
- HHSN268200900048C/PHS HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- UL1TR000005/TR/NCATS NIH HHS/United States
- A-HL-13-002-001/HL/NHLBI NIH HHS/United States
- HHSN268200900049C/HL/NHLBI NIH HHS/United States
- HHSN268200900047C/HL/NHLBI NIH HHS/United States
- 01-HL10741/HL/NHLBI NIH HHS/United States
- R01 HL107241/HL/NHLBI NIH HHS/United States
- P30GM103337/GM/NIGMS NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- P30-AG21332/AG/NIA NIH HHS/United States
- UL1 TR000050/TR/NCATS NIH HHS/United States
- UL1TR000003/TR/NCATS NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1 TR000073/TR/NCATS NIH HHS/United States
- UL1 RR025755/RR/NCRR NIH HHS/United States
- UL1 TR001085/TR/NCATS NIH HHS/United States
- R01 HL130500/HL/NHLBI NIH HHS/United States
- HHSN268200900049C/PHS HHS/United States
- UL1TR000439/TR/NCATS NIH HHS/United States
- UL1 TR000002/TR/NCATS NIH HHS/United States
- HHSN268200900047C/PHS HHS/United States
- UL1 TR000105/TR/NCATS NIH HHS/United States
- UL1TR001064/TR/NCATS NIH HHS/United States
- UL1RR024134/RR/NCRR NIH HHS/United States
- R01 HL107257/HL/NHLBI NIH HHS/United States
- UL1TR000075/TR/NCATS NIH HHS/United States
- P30 AG021332/AG/NIA NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States